TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04082936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imvotamab
Description: Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imvotamab
Description: Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imvotamab
Description: Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imvotamab
Description: Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imvotamab
Description: Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imvotamab
Description: Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
Study: NCT02501551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: 160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
Study: NCT01946035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin XL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00894842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
Study: NCT01131299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 tablets PO 3 times a day for 12-14 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets PO 3 times a day for 12-14 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha cyclodextrin
Description: 2g PO 3 times a day for 12-14 weeks
Study: NCT01605994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution
Study: NCT02279433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS6051b
Description: DS-6051b 50 mg and 200 mg capsules for oral administration
Study: NCT01551758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI
Description: FF/VI

Intervention type: OTHER
Group type: OTHER
Intervention: Existing Maintenance Therapy
Description: Existing Maintenance Therapy:~* Long acting bronchodilator therapy alone~* ICS alone or in combination with a long acting bronchodilator~* Triple maintenance therapy
Study: NCT01605994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution
Study: NCT00189423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)
Description: The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.~The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR.
Study: NCT03364608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS MDI 90 μg
Description: AS MDI 90 μg (2 actuations of 45 μg/actuation)
Study: NCT01131299

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpha cyclodextrin
Description: 2g PO 3 times a day for 12-14 weeks
Study: NCT00189423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardiopulmonary resuscitation (S-CPR)
Description: Conventional standard cardiopulmonary resuscitation (S-CPR)
Study: NCT00586157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
Study: NCT03508869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirvaso® (brimonidine) topical gel, 0.33%
Description: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport®
Description: Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
Description: Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
Study: NCT00746902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: Active nCPAP
Study: NCT00062764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actos (Pioglitazone)
Description: Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
Study: NCT01179230

Intervention type: OTHER
Intervention: SPECT imaging
Description: Dipyridamole stress testing 0.57 mg/kg

Intervention type: OTHER
Intervention: PET imaging
Description: Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
Study: NCT01318681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Description: cetirizine 10 mg over encapsulated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate
Description: nasal spray 25ug per dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a placebo nasal spray and placebo capsule are available for double dummy treatment
Study: NCT03116126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: 2mg oral daily tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive oral daily tablet
Study: NCT04474132

Intervention type: DEVICE
Group type: OTHER
Intervention: toxoplasma ICT IgG-IgM BK
Description: a point-of-care device, using blood from finger stick to measure the presence or absence of anti Toxoplasma gondii antibody
Study: NCT03901586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction assessment
Description: Patient will be asked to assess their satisfaction concerning the Richter procedure and its long term effect

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life
Description: The Quality of life will be assessed with 3 questionnaires (I-Qol / PISQ-12/PFDI-20)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gynecological assessment
Description: An optional gynecological consult is proposed to the patients to better estimate the gynecological long-term impact of the procedure
Study: NCT01518413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
Study: NCT04736693

Intervention type: DRUG
Intervention: Raloxifene
Description: Raloxifene dispensing claim is used as the reference group.

Intervention type: DRUG
Intervention: Zoledronic Acid
Description: Zoledronic Acid dispensing claim is used as the exposure group.
Study: NCT04312581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: 3 sessions of radial- extracorporeal shock wave therapy rESWT one week apart, 2000-3000 impulses at 0.25-0.84 millijoule /mm2with a pressure 2.8 bar and 15 Hz frequency.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: physical \& occupational therapy
Study: NCT00673504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Sunitinib
Description: Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 1.000 mg/m2 d1,8,15q4weeks
Study: NCT00573833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study: NCT02235857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIPOSORBER® LA-15 System
Description: LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
Study: NCT02799706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: approved GnRH agonist
Description: A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: .As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: .As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
Study: NCT04424303

Intervention type: DRUG
Intervention: Tofacitinib
Description: Observational study
Study: NCT00686023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: internal fixation (DHS - richard nail)
Description: internal fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: internal fixation (inflatable PFN by DISCOTEC)
Description: internal fixation
Study: NCT04027972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Neostigmine and Glycopyrrolate
Description: Intravenous or transdermal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Box by Dynatronics
Description: Electric field conducting drugs through the skin without compromising its integrity
Study: NCT03364608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS MDI 180 µg
Description: AS MDI 180 μg (2 actuations of 90 μg/actuation)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo MDI (2 actuations)
Study: NCT00746902

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: nCPAP
Description: Active nCPAP
Study: NCT03364608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil 90 μg
Description: Proventil 90 μg (1 actuation of 90 μg/actuation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil 180 μg
Description: Proventil 180 μg (2 actuations of 90 μg/actuation)
Study: NCT01793051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
Study: NCT03466489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floraseal
Description: FloraSeal is a cyanoacrylate-based sealant used in the prevention of surgical site infections.
Study: NCT03027804

Intervention type: PROCEDURE
Intervention: Ross Operation
Description: Replacement of the aortic valve by means of pulmonary artery autograft
Study: NCT03616665

Intervention type: OTHER
Group type: OTHER
Intervention: CBASPersonalized
Description: In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home.~Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented.
Study: NCT03535233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil 5 % Topical Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate
Study: NCT01076634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
Study: NCT03284242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treg
Description: Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
Study: NCT02731014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry Needling targeting the posterior musculature of the cervical and thoracic spine.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: Sham Dry Needling performed with Park sham acupuncture needles (Acuprime, UK) will be used to perform sham dry-needling. The device consists of 2 plastic tubes that slide into one another and cause a pricking sensation when pushed against the skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual Therapy
Description: Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.
Study: NCT04222114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The treatment of investigator choice
Description: the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
Study: NCT00141661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04494700 - Low Dose Arm
Description: 30 mg loading dose for 6 days, followed by 10 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04494700 - High Dose Arm
Description: 60 mg loading dose for 6 days, followed by 20 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching placebo.
Study: NCT02521181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lower Dose Sodium Bicarbonate
Description: Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher Dose Sodium Bicarbonate
Description: Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
Study: NCT00904748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate 100 mg CT
Description: sildenafil citrate 100 mg CT, single dose without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate 100 mg CT
Description: sildenafil citrate 100 mg CT, single dose with water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra®
Description: sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
Study: NCT01311401

Intervention type: OTHER
Intervention: NONE intervention
Description: NONE intervention

Intervention type: OTHER
Intervention: NONE intervention
Description: NONE intervention
Study: NCT04225572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy: Dependent on Patient's Needs
Description: Therapeutic exercise:~* ROM: Begin with passive upper extremity ROM and progress to active ROM.~* Strengthening: Progressive upper extremity resistive exercises starting with light weights.~* Aerobic: Select a suitable, individual aerobic exercise program (walking, yoga, etc.) Manual therapy~* Soft tissue mobilization, myofascial release, and stretching of identified tight and stiff tissue.~Lymphedema treatment~* Manual lymph drainage: Gentle lymphatic massage to lymph nodes and vessels by PT for 1-2 weeks. Instruct patient in self MLD to perform 1-2×/day for 10 minutes during the remaining weeks.~* Compression therapy: Gradient compression bandaging for daily wear with activities and exercise for 1-2 weeks. Instruct in self compression bandaging or issue a compression garment to wear with exercise or activity, or with worsening symptoms of AWS (i.e. cording extends down arm) or lymphedema.
Study: NCT03580954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.
Study: NCT03239613

Intervention type: OTHER
Group type: OTHER
Intervention: POHIM-CCRT
Description: postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
Study: NCT04015167

Intervention type: DEVICE
Intervention: T2 Alpha Tibia Nailing System
Description: The T2 Alpha Tibia Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
Study: NCT03959696

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Notification
Description: Clinicians will be notified of their patients aged 76-85 with an upcoming, non urgent visit who are due for colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Notification
Description: Clinicians will be notified of their patients aged 76-85 with an upcoming, non urgent visit who are due for colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The 2-hour continuing medical education course in shared decision making, simulated patient interaction to practice skills, and monthly calls for a year to review difficult cases with clinical and shared decision making experts.
Study: NCT03309644

Intervention type: OTHER
Intervention: Peripheral nerve blockade
Description: Participants who receive a peripheral nerve block identified through the medical chart.

Intervention type: OTHER
Intervention: No peripheral nerve blockade
Description: Participants who did not receive a peripheral nerve block identified through the medical chart.